Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody.

• Tác giả: Yuansong Bai, Zhiwei Chang, Nianyong Chen, Xiaohong Chen, Xinyue Chen, Meiyu Fang, Wenlin Gai, Ye Guo, Guangyuan Hu, Xiaoming Huang, Yanjing Huang, Shanghua Jing, Weidong Li, Zhendong Li, Jinguan Lin, Xianling Liu, Yanyan Liu, Song Qu, Liangfang Shen, Yan Sun, Jian Wu, Liangzhi Xie, Kunyu Yang, Jiang Yi, Shurong Zhang, Songnan Zhang, Tao Zhang, Qiang Zhou
• Ngôn ngữ: eng
• Ký hiệu phân loại: 629.2223 Motor land vehicles, cycles
• Thông tin xuất bản: Ireland : Cancer letters , 2025
• Bộ sưu tập: NCBI
• ID: 177952

Tóm tắt

Treatment options for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are limited, especially for patients who progress after immune checkpoint inhibitor (ICI) therapy. This phase Ib study investigates the efficacy and safety of SCT200, an epidermal growth factor receptor (EGFR) antibody, combined with paclitaxel or docetaxel in R/M HNSCC patients who have failed both platinum-based chemotherapy and programmed cell death protein 1 (PD-1) inhibitors. This was a multicenter, open-label study enrolling patients with resistance or intolerance to platinum-based chemotherapy and PD-1 inhibitors. Patients received intravenous SCT200 (6 mg/kg weekly for 12 weeks, followed by 8 mg/kg every two weeks). Paclitaxel (80 mg/m